In a new joint research venture worth up to $100 million, MethylGene Inc. and Pharmion are developing novel small-molecule inhibitors targeting sirtuins, a distinct member of the histone deacetylase enzyme class implicated in cell survival and death. (BioWorld Today)

With the U.S. approval Friday of Anesiva's lidocaine product Zingo, hospitalized children will have something less to fear: needle sticks from i.v. insertions and blood draws. (BioWorld Today)